Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Depot haloperidol decanoate for schizophrenia.

S Quraishi1, A David

  • 1Department of Psychological Medicine, King College School of Medicine and Dentistry, 103 Denmark Hill, London, UK, SE5 8AF. snq@hotmail.com

The Cochrane Database of Systematic Reviews
|May 5, 2000
PubMed
Summary

Haloperidol decanoate depot injections show significant benefits over placebo for schizophrenia treatment, reducing early departures and improving mental state. No differences were found compared to oral antipsychotics or other depot preparations.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The effectiveness of two psychomotor therapy programmes on physical fitness and physical self-concept in nonpsychotic psychiatric patients: a randomized controlled trial.

Clinical rehabilitation·2003
Same author

Interaction of proteinase 3 with CD11b/CD18 (beta2 integrin) on the cell membrane of human neutrophils.

Journal of leukocyte biology·2003
Same author

A novel combination of promoter and enhancers increases transgene expression in vascular smooth muscle cells in vitro and coronary arteries in vivo after adenovirus-mediated gene transfer.

Gene therapy·2003
Same author

Comparison of selection methods for optimizing genetic gain and gene diversity in a red pine ( Pinus resinosa Ait.) seedling seed orchard.

TAG. Theoretical and applied genetics. Theoretische und angewandte Genetik·2003
Same author

Mapping a gene for 46,XY gonadal dysgenesis by linkage analysis.

Clinical genetics·2003
Same author

Neurotransmission and viscoelasticity in the ovine fetal bladder after in utero bladder outflow obstruction.

American journal of physiology. Regulatory, integrative and comparative physiology·2003

Area of Science:

  • Psychiatry and Pharmacology
  • Clinical Neuroscience
  • Evidence-Based Medicine

Background:

  • Antipsychotic medications are the primary treatment for schizophrenia.
  • Oral administration poses challenges in quantifying compliance and adherence.
  • Depot injections, including haloperidol decanoate, offer long-term maintenance treatment options.

Purpose of the Study:

  • To evaluate haloperidol decanoate against oral antipsychotics and other depot preparations for schizophrenia.
  • To assess clinical, social, and economic outcomes of haloperidol decanoate treatment.

Main Methods:

  • Systematic review of randomized controlled trials identified through comprehensive database searches.
  • Inclusion criteria focused on schizophrenia patients comparing haloperidol decanoate with oral antipsychotics or other depots.

Related Experiment Videos

  • Outcomes assessed included mortality, global function, mental state, relapse, hospital admission, adverse effects, and treatment acceptability.

    • Main Results:

    • Haloperidol decanoate significantly reduced early study withdrawal and improved mental state compared to placebo.
    • No significant differences were observed between haloperidol decanoate and oral haloperidol in global impression, mental state, or side effects.
    • Comparisons with other depot antipsychotics revealed no differences in key outcomes like death, global impression, mental state, behavior, or side effects.

    Conclusions:

    • Haloperidol decanoate demonstrates potential benefits over placebo for schizophrenia symptom and behavior management, though supporting data is limited.
    • There are no clear differences between haloperidol decanoate and its oral counterpart, making administration choice a matter of clinical judgment.
    • Individual patient preference and tailored choices are recommended when selecting between haloperidol decanoate and other depot formulations due to lack of discernible differences.